Patents by Inventor Susan Kautz

Susan Kautz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dimer VEGF antagonist formulations
    Patent number: 8404638
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: January 4, 2012
    Date of Patent: March 26, 2013
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel Dix, Kelly Frye, Susan Kautz
  • VEGF ANTAGONIST FORMULATIONS
    Publication number: 20120178683
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: March 23, 2012
    Publication date: July 12, 2012
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel DIX, Kelly FRYE, Susan KAUTZ
  • VEGF Antagonist Formulations
    Publication number: 20120101035
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: January 4, 2012
    Publication date: April 26, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel Dix, Kelly Frye, Susan Kautz
  • VEGF antagonist formulations
    Patent number: 8110546
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: February 7, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel Dix, Kelly Frye, Susan Kautz
  • VEGF ANTAGONIST FORMULATIONS
    Publication number: 20100279933
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: July 13, 2010
    Publication date: November 4, 2010
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: DANIEL DIX, KELLY FRYE, SUSAN KAUTZ
  • VEGF antagonist formulations
    Publication number: 20060217311
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: March 22, 2006
    Publication date: September 28, 2006
    Inventors: Daniel Dix, Kelly Frye, Susan Kautz